CA2009402A1 - Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes - Google Patents

Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes

Info

Publication number: CA2009402A1
Authority: CA; Canada
Prior art keywords: benzydamine; cream; pain; treatment; herpes zoster
Prior art date: 1990-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2009402

Other languages

English (en)

Inventor

Attilio J. De Sanctis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Angelini Pharmaceuticals Canada Inc

Original Assignee

Angelini Pharmaceuticals Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-06

Filing date

1990-02-06

Publication date

1991-08-06

1990-02-06 Application filed by Angelini Pharmaceuticals Canada Inc filed Critical Angelini Pharmaceuticals Canada Inc

1990-02-06 Priority to CA 2009402 priority Critical patent/CA2009402A1/fr

1991-08-06 Publication of CA2009402A1 publication Critical patent/CA2009402A1/fr

Status Abandoned legal-status Critical Current

Links

CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 title claims abstract description 119
208000002193 Pain Diseases 0.000 title claims abstract description 79
230000036407 pain Effects 0.000 title claims abstract description 79
229960000333 benzydamine Drugs 0.000 title claims abstract description 60
150000003839 salts Chemical class 0.000 title claims abstract description 35
238000009834 vaporization Methods 0.000 title claims abstract description 12
230000008016 vaporization Effects 0.000 title claims abstract description 12
206010019972 Herpes viral infections Diseases 0.000 title 1
239000006071 cream Substances 0.000 claims abstract description 63
238000011282 treatment Methods 0.000 claims abstract description 47
208000007514 Herpes zoster Diseases 0.000 claims abstract description 30
210000003905 vulva Anatomy 0.000 claims abstract description 21
239000002253 acid Substances 0.000 claims abstract description 16
208000015181 infectious disease Diseases 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims description 22
238000009472 formulation Methods 0.000 claims description 20
HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 claims description 18
229960001689 benzydamine hydrochloride Drugs 0.000 claims description 18
230000000699 topical effect Effects 0.000 claims description 17
239000004480 active ingredient Substances 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
230000001154 acute effect Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 5
208000004296 neuralgia Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims 4
239000008250 pharmaceutical cream Substances 0.000 claims 2
239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 18
239000000839 emulsion Substances 0.000 description 12
238000002430 laser surgery Methods 0.000 description 12
230000000694 effects Effects 0.000 description 11
150000002148 esters Chemical class 0.000 description 10
239000012071 phase Substances 0.000 description 10
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
230000006378 damage Effects 0.000 description 9
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 8
230000003902 lesion Effects 0.000 description 8
206010036376 Postherpetic Neuralgia Diseases 0.000 description 7
208000027418 Wounds and injury Diseases 0.000 description 7
230000000202 analgesic effect Effects 0.000 description 7
208000014674 injury Diseases 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
-1 fatty acid esters Chemical class 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000007764 o/w emulsion Substances 0.000 description 6
230000003110 anti-inflammatory effect Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
230000035876 healing Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
208000009458 Carcinoma in Situ Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241001313288 Labia Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000009760 functional impairment Effects 0.000 description 4
201000004933 in situ carcinoma Diseases 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
210000000273 spinal nerve root Anatomy 0.000 description 4
239000005711 Benzoic acid Substances 0.000 description 3
208000001387 Causalgia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000003251 Pruritus Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000003444 anaesthetic effect Effects 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
235000017663 capsaicin Nutrition 0.000 description 3
229960002504 capsaicin Drugs 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
210000000609 ganglia Anatomy 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
206010059313 Anogenital warts Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
208000000907 Condylomata Acuminata Diseases 0.000 description 2
206010013886 Dysaesthesia Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
206010029240 Neuritis Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102100024304 Protachykinin-1 Human genes 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
101800003906 Substance P Proteins 0.000 description 2
208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
210000003029 clitoris Anatomy 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229940059082 douche Drugs 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000024312 invasive carcinoma Diseases 0.000 description 2
230000000622 irritating effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
210000001640 nerve ending Anatomy 0.000 description 2
230000007433 nerve pathway Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000036280 sedation Effects 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
210000003594 spinal ganglia Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
ZCZQDTUCMRSEAS-DHDLBFDBSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n-(4-hydroxyphenyl)acetamide;phosphoric acid Chemical compound OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZCZQDTUCMRSEAS-DHDLBFDBSA-N 0.000 description 1
XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
244000144927 Aloe barbadensis Species 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
240000008574 Capsicum frutescens Species 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
206010019842 Hepatomegaly Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
239000010103 Podophyllin Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010037898 Rash vesicular Diseases 0.000 description 1
241000208292 Solanaceae Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241001279009 Strychnos toxifera Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
206010068268 Tumour compression Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010054932 Vulvar dysplasia Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001994 activation Methods 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000891 anti-reserpine Effects 0.000 description 1
230000000794 anti-serotonin Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001390 capsicum minimum Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
239000007957 coemulsifier Substances 0.000 description 1
238000002573 colposcopy Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
238000003304 gavage Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940124583 pain medication Drugs 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000005223 peripheral sensory neuron Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229940068582 podophyllin Drugs 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
102000027509 sensory receptors Human genes 0.000 description 1
108091008691 sensory receptors Proteins 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003093 somatogenic effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
229960005453 strychnine Drugs 0.000 description 1
231100000456 subacute toxicity Toxicity 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
229940072651 tylenol Drugs 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
208000013464 vaginal disease Diseases 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
208000013013 vulvar carcinoma Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229940112501 zostrix Drugs 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA 2009402 1990-02-06 1990-02-06 Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes Abandoned CA2009402A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2009402 CA2009402A1 (fr)	1990-02-06	1990-02-06	Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2009402 CA2009402A1 (fr)	1990-02-06	1990-02-06	Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes

Publications (1)

Publication Number	Publication Date
CA2009402A1 true CA2009402A1 (fr)	1991-08-06

Family

ID=4144216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2009402 Abandoned CA2009402A1 (fr)	1990-02-06	1990-02-06	Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes

Country Status (1)

Country	Link
CA (1)	CA2009402A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018007288A1 (fr) *	2016-07-08	2018-01-11	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	Composé pharmaceutique contenant du céfuroxime.
JP2018504439A (ja) *	2015-02-09	2018-02-15	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	粘膜炎の治療のための組成物及び方法

1990
- 1990-02-06 CA CA 2009402 patent/CA2009402A1/fr not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018504439A (ja) *	2015-02-09	2018-02-15	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	粘膜炎の治療のための組成物及び方法
CN107873024A (zh) *	2015-02-09	2018-04-03	塞尔利克斯生物私人有限公司	用于治疗粘膜炎的组合物和方法
EP3256459B1 (fr) *	2015-02-09	2022-07-13	Cellixbio Private Limited	Compositions et procédés destinés au traitement de la mucosite
WO2018007288A1 (fr) *	2016-07-08	2018-01-11	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	Composé pharmaceutique contenant du céfuroxime.
CN109562058A (zh) *	2016-07-08	2019-04-02	方济各安吉利克化学联合股份有限公司	包含苄达明的药物组合物
US20190224168A1 (en) *	2016-07-08	2019-07-25	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	Pharmaceutical composition comprising benzydamine
EA037435B1 (ru) *	2016-07-08	2021-03-26	Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.	Фармацевтическая композиция, содержащая бензидамин

Publication	Publication Date	Title
EP0946155B1 (fr)	2006-03-22	Composition pharmaceutique destinee au traitement de l'incontinence fecale et du prurit anal
US10434059B2 (en)	2019-10-08	Medicament for the treatment of viral skin and tumour diseases
EP0714300A1 (fr)	1996-06-05	Methode de modulation de la reponse sexuelle chez l'homme
JP2002541097A (ja)	2002-12-03	線維筋痛症及び関連症状の治療におけるフルピルチン
JPS61277620A (ja)	1986-12-08	排尿困難治療剤
CN1298309A (zh)	2001-06-06	治疗肛门区疼痛的方法及其组合物
US20140011838A1 (en)	2014-01-09	Compositions and methods for treating warts associated with viral infections
KR100851938B1 (ko)	2008-08-12	방광 질환의 치료를 위한 카프-오피에이트 작용제
CA2009402A1 (fr)	1991-08-06	Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes
KR20160089518A (ko)	2016-07-27	골반-회음부 기능의 병리학적 병태들을 예방하고/거나 치료하기 위한 par-1 길항제들의 용도
US5134165A (en)	1992-07-28	Method of treatment for loss of vision due to ophthalmic surgery
RU2445100C2 (ru)	2012-03-20	Консервативный способ комплексного лечения острых и хронических анальных трещин
WO2017100324A1 (fr)	2017-06-15	Traitement d'association pour traiter les troubles de la baisse du désir sexuel chez la femme
AU696815C (en)	1999-06-24	Methods for modulating the human sexual response
CA2591917C (fr)	2009-05-19	Methode de traitement des etats douloureux de la region anale et compositions correspondantes
UA146868U (uk)	2021-03-31	Фармацевтична композиція для лікування болю
CN118319910A (zh)	2024-07-12	托吡卡胺在制备抗瘙痒药物中的应用
JP2004518646A (ja)	2004-06-24	腹圧性尿失禁を治療するための局所用組成物および方法
JPWO2005058878A1 (ja)	2007-07-12	月経困難症の予防および／または治療剤
KR20020035131A (ko)	2002-05-09	덱스라족산의 건선 치료 용도
Panchmatia	2010	Diclofenac 4% spray for acute pain and inflammation
GRAMOL	0	Two was ronaveL BETTER.
MOLAR	0	Dissertation Submitted to Maharashtra University of Health Sciences, Nashik In the Partial Fulfillment of Regulations for the Award of the Degree of
HK1064036B (en)	2007-04-04	Kapp-opiate agonists for the treatment of bladder dieseases
MXPA98001222A (en)	1999-01-11	Quecontain composition mefenamic acid in association with code

Legal Events

Date	Code	Title	Description
1990-02-06	EEER	Examination request
1992-08-08	FZDE	Dead